Loading company
CytomX Therapeutics, Inc.
CTMX · Nasdaq · ·
Next earnings: November 5, 2026
$2.74+2.0%Sep 29 close
- 1M
- -14.6%
- 6M
- -37.9%
- 1Y
- -14.1%
- 5Y
- -49.4%
CTMX · Nasdaq · ·
Next earnings: November 5, 2026
$2.74+2.0%Sep 29 close
CytomX Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.4M | $18.7M | -92.40% |
| Profit | -$20.7M | -$154K | -13,319.48% |
| Profit per share | -$0.69 | -$0.39 | -76.92% |
| Free Cash Flow | -$18.1M | -$15.8M | -14.50% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“CytomX had a productive second quarter as we advanced and broadened the Varseta-M program, the only EpCAM-directed antibody drug conjugate (ADC) in clinical development and a potentially best-in-class ADC for colorectal cancer. As we drive Varseta-M towards its first registrational study in late-line CRC, we are also accelerating our broader vision of earlier line utilization in CRC combination regimens, while also initiating development in additional gastrointestinal cancers of high unmet need,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from CytomX Therapeutics, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
CytomX Therapeutics, Inc. has no earnings call transcript available.